

MAR 26 2004

VERTEBRON, Inc.

510(k) Notification

K040003

510(k) SUMMARY OF SAFETY & EFFECTIVENESS

SUBMITTER	Vertebron, Ltd. Stratford, CT 06614
CONTACT PERSON	Bruce Khalili Vice President, Research & Development
DATE PREPARED	December 23, 2003
CLASSIFICATION	Spinal Interlaminar Fixation Orthosis; KWQ Class II
COMMON NAME	Anterior Cervical Plate
PROPRIETARY NAME	Vertebron SCP™ Cervical Plate System
PREDICATE DEVICES	Centerpulse Spine-Tech K022344 Thcken Surgical K010466 Blackstone Medical K030595
DEVICE DESCRIPTION	The device consists of a system of implantable metal plates and screws intended the purpose of aiding in spinal fusion. The system also includes various hand tool used to assist in implantation of the system. Implantable components are composed of titanium alloy meeting the requirements of ASTM F136-98. The device is supplied non-sterile and is intended for sterilization by hospital personnel.
TESTING	The device has been tested in accordance with the requirements prescribed in ASTM F1717. The device was found to perform comparably to other cervical plate systems.

Page 1 of 1



MAR 26 2004

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Mr. Bruce Khalili
Vice President, Research & Development
Vertebron, Inc.
136 Albert Avenue
Stratford, Connecticut 06614

Re: K040003
Trade/Device Name: Vertebron SCP™ Cervical Plate System
Regulation Number: 21 CFR 888.3060
Regulation Name: Spinal intervertebral body fixation orthosis
Regulatory Class: II
Product Code: KWQ
Dated: December 30, 2003
Received: January 2, 2004

Dear Mr. Khalili:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Mr. Bruce Khalili

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "Celia M. Witten", is written over the typed name.

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative
and Neurological Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

VERTEBRON, Inc.
510(k) Notification

STATEMENT FOR INDICATIONS FOR USE

510(k) Number: K040003

Device Name: Vertebon SCP™ Cervical Plate System

Indications for Use:

The Vertebon SCP™ Cervical Plate System is intended for anterior interbody fixation of the cervical spine. The system is indicated for use in the temporary stabilization of the anterior spine during the development of cervical spine fusions in patients with degenerative disc disease (as defined by neck pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies), trauma (including fractures), tumors, deformity (defined as kyphosis, lordosis, or scoliosis), pseudoarthrosis, and/or failed previous fusions. The SCP Cervical Plate System can be implanted in the sub-axial cervical spine from the C3 through C7 levels.

Prescription Use: Yes

DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED

Concurrence of CDRH, Office of Device Evaluation

for Mark A. Melhus
(Division Chief)

Division of General, Restorative,
and Neurological Devices

Page 1 of 1

Vertebon SCP™ Cervical Plate System
510(k) Number K040003